clinical trials

News

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

News

An obesity therapy developed by Hengrui Pharma and Kailera is being prepared for its first regulatory submission, in China.

News

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

News

Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.

News

Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.

Patients

pharmaphorum spoke with Leslie Oley Wilberforce, Evidation's new CEO, about the company's unique approach to real-world data and her future plans.